These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28696785)

  • 1. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
    Allam MM; El Gazzar WB
    Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
    Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
    World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats.
    Yang ZR; Wang HF; Zuo TC; Guan LL; Dai N
    BMC Pharmacol Toxicol; 2016 Apr; 17():16. PubMed ID: 27075663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active form of vitamin D ameliorates non-alcoholic fatty liver disease by alleviating oxidative stress in a high-fat diet rat model.
    Zhu CG; Liu YX; Wang H; Wang BP; Qu HQ; Wang BL; Zhu M
    Endocr J; 2017 Jul; 64(7):663-673. PubMed ID: 28539530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.
    Wang Y; Parlevliet ET; Geerling JJ; van der Tuin SJ; Zhang H; Bieghs V; Jawad AH; Shiri-Sverdlov R; Bot I; de Jager SC; Havekes LM; Romijn JA; Willems van Dijk K; Rensen PC
    Br J Pharmacol; 2014 Feb; 171(3):723-34. PubMed ID: 24490861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
    Ding X; Saxena NK; Lin S; Gupta NA; Anania FA
    Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
    Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
    Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease.
    Pereira ENGDS; Silvares RR; Flores EEI; Rodrigues KL; Ramos IP; da Silva IJ; Machado MP; Miranda RA; Pazos-Moura CC; Gonçalves-de-Albuquerque CF; Faria-Neto HCC; Tibiriça E; Daliry A
    PLoS One; 2017; 12(6):e0179654. PubMed ID: 28628674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
    Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
    Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary glycotoxins exacerbate progression of experimental fatty liver disease.
    Leung C; Herath CB; Jia Z; Goodwin M; Mak KY; Watt MJ; Forbes JM; Angus PW
    J Hepatol; 2014 Apr; 60(4):832-8. PubMed ID: 24316518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
    Kawaguchi T; Itou M; Taniguchi E; Sata M
    Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Lee JA; Gu MJ; Lee YR; Kim Y; Choi I; Kim D; Ha SK
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr
    Bijnen M; Beelen N; Wetzels S; Gaar JV; Vroomen M; Wijnands E; Scheijen JL; van de Waarenburg MPH; Gijbels MJ; Cleutjens JP; Biessen EAL; Stehouwer CDA; Schalkwijk CG; Wouters K
    Sci Rep; 2018 Oct; 8(1):15256. PubMed ID: 30323247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
    Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
    Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
    Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
    World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats.
    Liu J; Han L; Zhu L; Yu Y
    Lipids Health Dis; 2016 Feb; 15():27. PubMed ID: 26868515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice.
    Valdecantos MP; Pardo V; Ruiz L; Castro-Sánchez L; Lanzón B; Fernández-Millán E; García-Monzón C; Arroba AI; González-Rodríguez Á; Escrivá F; Álvarez C; Rupérez FJ; Barbas C; Konkar A; Naylor J; Hornigold D; Santos AD; Bednarek M; Grimsby J; Rondinone CM; Valverde ÁM
    Hepatology; 2017 Mar; 65(3):950-968. PubMed ID: 27880981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.